Lutetium Lu-177 dotatate

Lutathera attaches beta-emitting lutetium-177 to the same somatostatin-targeting dotatate peptide used in Ga-68 imaging. It was the first US-approved peptide receptor radionuclide therapy, or PRRT, in 2018. The imaging isotope and treatment isotope serve different functions.

Dotatate binds somatostatin receptor subtype 2 and is internalized by receptor-rich neuroendocrine tumor cells. Lu-177 delivers short-range beta radiation that damages tumor DNA and nearby cells, concentrating exposure at the target while sparing much healthy tissue. The theranostic pairing uses receptor imaging to confirm the target before treatment. NETTER-1 found markedly longer progression-free survival than high-dose octreotide in advanced midgut tumors. A concurrent amino-acid infusion helps protect the kidneys.

Supporting references: survival.

FDA’s 2018 approval was for adults with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors, with a later adolescent extension. This includes foregut, midgut and hindgut sites. Eligibility is established with appropriate receptor imaging such as Ga-68 dotatate. The described course is four IV infusions about eight weeks apart under specialist care.

Supporting references: approved.

Nausea/vomiting, partly from the protective amino-acid infusion, fatigue and low blood counts are common. More serious issues include marrow suppression, secondary myelodysplastic syndrome or leukemia, renal/hepatic toxicity and a temporary neuroendocrine hormonal crisis. Allergy can include angioedema of the face or throat. Radiation exposure and fertility effects require product-specific precautions.